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Introduction: Administration of mesenchymal stem cells (MSCs) has been shown to improve renal function in
rodent models of chronic kidney disease (CKD), in part by reducing intrarenal inflammation and suppressing
fibrosis. CKD in cats is characterized by tubulointerstitial inflammation and fibrosis, and thus treatment with MSCs
might improve renal function and urinary markers of inflammation in this disease. Therefore, a series of pilot studies
was conducted to assess the safety and efficacy of intravenous administration of allogeneic adipose-derived MSCs
(aMSCs) in cats with naturally occurring CKD.
Methods: Cats enrolled in these studies received an intravenous infusion of allogeneic aMSCs every 2 weeks
collected from healthy, young, specific pathogen-free cats. Cats in pilot study 1 (six cats) received 2 × 106
cryopreserved aMSCs per infusion, cats in pilot study 2 (five cats) received 4 × 106 cryopreserved aMSCs per
infusion, and cats in pilot study 3 (five cats) received 4 × 106 aMSCs cultured from cryopreserved adipose. Serum
biochemistry, complete blood count, urinalysis, urine protein, glomerular filtration rate, and urinary cytokine
concentrations were monitored during the treatment period. Changes in clinical parameters were compared
statistically by means of repeated measures analysis of variance (ANOVA) followed by Bonferroni’s correction.
Results: Cats in pilot study 1 had few adverse effects from the aMSC infusions and there was a statistically
significant decrease in serum creatinine concentrations during the study period, however the degree of decrease
seems unlikely to be clinically relevant. Adverse effects of the aMSC infusion in cats in pilot study 2 included
vomiting (2/5 cats) during infusion and increased respiratory rate and effort (4/5 cats). Cats in pilot study 3 did not
experience any adverse side effects. Serum creatinine concentrations and glomerular filtration rates did not change
significantly in cats in pilot studies 2 and 3.
Conclusions: Administration of cryopreserved aMSCs was associated with significant adverse effects and no
discernible clinically relevant improvement in renal functional parameters. Administration of aMSCs cultured from
cryopreserved adipose was not associated with adverse effects, but was also not associated with improvement in
renal functional parameters.
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Chronic kidney disease (CKD) is a common condition in
elderly cats and is characterized by tubulointerstitial in-
flammation, tubular atrophy and interstitial fibrosis with
subsequent progressive loss of renal function [1,2]. Cur-
rently there is no definitive therapy short of renal trans-
plant to improve kidney function in cats with CKD.
Therefore, novel and effective therapeutic options are
highly desired for treating this disease in cats.
Recently, a number of studies have suggested the use
of mesenchymal stem cells (MSCs) as a novel treatment
option for management of CKD, based on encouraging
data from rodent studies [3-7]. There have been several
rationales advanced for the use of MSCs for treatment
of CKD. Rodent studies have suggested that MSCs may
incorporate into the renal parenchyma and give rise to
new renal tubular cells, though the process appears to
be relatively inefficient [8-17]. MSCs also exert potent
anti-inflammatory and antifibrotic effects and may there-
fore indirectly improve renal function by reducing disease-
associated inflammation and fibrosis through paracrine
effects [3-7]. For example, MSCs have been shown to in-
hibit lymphocyte proliferation and cytokine production,
suppress dendritic cell function, and suppress interferon γ
(IFNγ) production by natural killer (NK) cells [18].
Since inflammation appears to be present at all stages
of CKD in cats, the immunomodulatory actions of MSCs
are appealing as an alternative means of suppressing
intrarenal inflammation long term and with fewer side
effects than with conventional anti-inflammatory drugs.
In the majority of experimentally-induced CKD models
investigated, MSC administration resulted in improved
renal function, decreased intrarenal inflammation, and
reduction of renal fibrosis [3-7]. Thus, MSC therapy
may be an effective new approach to slow the progres-
sion of CKD and improve renal function.
Previous studies have demonstrated that cultured MSCs
can be administered intravenously to rodents as well as to
humans. However, in rodent models there is a significant
risk of pulmonary thrombosis when high numbers of
MSCs are rapidly administered intravenously [19]. Alter-
native routes of delivery have included injection via the
renal artery, injection directly into the renal parenchyma,
and injection into the renal subcapsular space [3-7]. One
potential advantage of intravenous delivery compared to
other routes may be the induction of renotropic paracrine
effects following intravenous administration of MSCs [20].
Based on compelling results from rodent studies, we
conducted a series of pilot studies to investigate the
safety and potential efficacy of adipose-derived MSC
(aMSC) therapy as a treatment for cats with naturally
occurring CKD. These studies were designed to test the
hypothesis that allogeneic cryopreserved aMSCs could
be safely administered to cats with CKD and wouldresult in improvement in kidney function. For this study,
aMSCs were derived from allogeneic, healthy, specific
pathogen-free (SPF) donor cats and cryopreserved, ei-
ther as cells or adipose tissue, prior to intravenous ad-
ministration to study cats. One primary study endpoint
was to determine safety and potential adverse effects of
repeated intravenous administration of cryopreserved
aMSCs. The second major endpoint was to determine
whether repeated MSC administrations were associated
with improvement in renal function or urinary markers
of intrarenal inflammation. These studies produced evi-
dence of modest, but unlikely to be clinically significant,
improvement in renal function but also showed evidence
of significant adverse effects associated with intravenous
administration of higher doses of cryopreserved aMSCs.
Methods
Study cats
Cats with stable CKD, serum creatinine 1.6 to 5.0 mg/dl,
were recruited from the patient population at the Veter-
inary Teaching Hospital at Colorado State University.
Cats were determined to have stable CKD based on two
repeated biochemical evaluations performed at least 2
weeks apart and ultrasonographic evidence of CKD. Pre-
treatment evaluation included complete blood count
(CBC), biochemistry profile, urinalysis, urine culture,
blood pressure, total T4, urine protein creatinine ratio
(UPC), feline leukemia/feline immunodeficiency virus
serology, and a renal ultrasound. Cats were excluded
from the study if they had evidence of ureteroliths, py-
elonephritis, anatomic abnormalities such as polycystic
kidney disease or masses, uncontrolled hypertension, or
concurrent systemic disease. Administration of concur-
rent supportive therapies was allowed provided there
were no changes in therapy during the study period. The
study was approved by the Institutional Animal Care
and Use Committee at Colorado State University (#10-
1603A and 11-2915A), and all owners reviewed and
signed consent forms prior to participation in the study.
aMSC preparation and administration: pilot studies 1 and 2
MSCs were isolated from adipose tissue of donor SPF cats
obtained from the same subcutaneous site on the ventral
abdomen just caudal to the umbilicus, as previously de-
scribed [21,22]. For isolation of the stromal vascular frac-
tion, the tissue was minced and digested with 1 mg/ml
collagenase (Sigma Aldrich, St Louis, MO, USA) for 30 mi-
nutes at 37°C. The sample was centrifuged, and the stromal
vascular fraction was plated in MSC medium (low glucose
Dulbecco’s modified Eagle medium (DMEM), 100 U/ml
penicillin, 100 μg/ml streptomycin, 2 μM L-glutamine,
1% essential amino acids without L-glutamine, 1% non-
essential amino acids, 0.075% sodium bicarbonate (Invitrogen/
Gibco, Carlsbad, CA, USA) plus 15% fetal bovine serum
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were incubated until approximately 70% confluent with
media changes every 2 to 3 days. After reaching passage
3, cells were harvested, divided into treatment aliquots
in freezing medium (11% dimethyl sulfoxide, 14% MSC
medium, 75% fetal bovine serum), and stored in liquid
nitrogen for no greater than 1 year prior to use. For in-
jection in pilot studies 1 and 2, cryopreserved cells were
removed from liquid nitrogen, incubated in MSC medium
for 10 minutes, washed three times in Dulbecco’s phos-
phate buffered saline (DPBS; Sigma) and then counted
and checked for viability using Trypan Blue (cells with less
than 95% viability were not used). For cats in pilot study 1,
2 × 106 cells were resuspended in 5 ml Hank’s balanced
salt solution (HBSS) with 200 IU heparin sulfate and ad-
ministered slowly by hand over 15 minutes; aMSCs were
administered at weeks 0, 2 and 4. For cats in pilot study 2,
4 × 106 cells were initially resuspended in 10 ml HBSS
with 200 IU heparin sulfate and administered as a slow
intravenous push over 30 minutes. However, the first cat
to receive MSCs in this manner experienced an increased
respiratory rate. Subsequently, cells for the high-dose
group were resuspended in 20 ml HBSS/200 IU heparin
and administered over 45 to 60 minutes with a syringe
pump with frequent agitation of the syringe to prevent set-
tling of the cells. Cats in pilot study 2 received aMSCs at
weeks 2, 4, and 6. All three injections received by cats
treated in pilot studies 1 and 2 were from the same donor
cat. A total of four donor cats were used to provide
aMSCs for those studies.
MSC preparation and administration: pilot study 3
MSCs were isolated from adipose tissue of donor SPF cats
as described above. For preparation of the adipose tissue
for cryopreservation, the tissue was minced and divided
into 1-g aliquots in 1 ml of freezing medium (11% di-
methyl sulfoxide, 14% MSC medium, 75% fetal bovine
serum), and stored in liquid nitrogen for no greater than 1
year prior to use. Cryopreserved adipose was then later
thawed, immediately washed twice with DPBS, and then
prepared for culture as described above. For injection in
pilot study 3 cats, cells were harvested by trypsinization at
passage 3 and resuspended in 10 ml DPBS with 200 IU
heparin sulfate and administered as a slow intravenous
push over 20 minutes. Cats in pilot study 3 received
aMSCs at weeks 2, 4, and 6. All three injections received
by cats treated in pilot study 3 were from different donor
cats given in a prerandomized order. A total of three
donor cats were used to provide aMSCs for the study.
Characterization of MSCs
aMSCs cultured from cryopreserved adipose tissue were
characterized by surface marker expression using flow
cytometry and a panel of crossreactive antibodiesspecific for surface determinants expressed by MSCs
from other species [23-26]. Specifically, feline aMSCs
were analyzed for surface expression of CD44 (anti-
mouse/human, antibody clone:IM7, eBioscience, San
Diego, CA, USA) and CD90 (anti-human, antibody
clone:eBio5E10, eBioscience). MSCs were also assessed
for expression of CD4 (anti-feline antibody clone: 3-4F4,
Southern Biotech, Birmingham, AL, USA) and major
histocompatibility complex (MHC) class II (anti-feline
antibody clone: TU39, BD Bioscience, San Jose, CA, USA).
Samples were analyzed using a Cyan ADP flow cytometer
(Beckman Coulter, Brea, CA, USA). Approximately 25,000
events were collected for analysis per sample.
In vitro differentiation assays were conducted to confirm
the multipotency of feline aMSCs, as assessed by their
ability to differentiate into three cell lineages (osteoblasts,
chondrocytes, and adipocytes) that are characteristic of
MSCs [27]. For differentiation into adipocytes, aMSCs at
confluency were incubated with MSC medium sup-
plemented with 0.5 μM dexamethasone (Sigma Aldrich),
50 μM indomethacin (Sigma Aldrich) and 0.5 μM 3-
isobutyl-1-methylxantine (Sigma Aldrich) for 3 weeks
with media changes every 3 to 4 days. Chondrogenic dif-
ferentiation medium consisted of DMEM 1 × (Cellgro,
Manassas, VA, USA) supplemented with 15% fetal bovine
serum (FBS; Cell Generation), 10 nM dexamethasone
(Sigma Aldrich), 10 ng/ml transforming growth factor
(TGF)-β (R&D Systems, Minneapolis, MN, USA), 50 μg/ml
ascorbic acid (Sigma Aldrich), and 40 μg/ml proline (Sigma
Aldrich). Osteogenic differentiation medium consisted of
MSC medium supplemented with 10 nM dexamethasone,
50 μM ascorbic acid, and 20 mM β-glycerophosphate
(Sigma Aldrich) At the end of the differentiation period,
cells were fixed with 10% neutral buffered formalin and
stained with Oil Red O (Sigma Aldrich) for presence of
lipid or with Alizarin Red (Sigma Aldrich) for the presence
of calcium [27]. Cell pellets from cartilage differentiation
were harvested and placed in OCT Compound (Sakura
Finetek USA, Inc., Torrance, CA, USA) and flash frozen
prior to staining with toluidine blue (Richard-Allan Scien-
tific, Kalamazoo, MI, USA) for cartilage matrix. aMSCs cul-
tured in MSC medium alone under identical conditions
were used as differentiation controls.
Clinical monitoring
Pilot study 1
Each treated cat underwent physical examination, weighing,
and routine blood work consisting of CBC, serum bio-
chemistry, urinalysis, and UPC immediately prior to aMSC
injection at week 0, and at week 2, 4.
Pilot study 2
Each treated cat underwent physical examination,
weighing, and routine blood work consisting of CBC,
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and 8. Each cat had a UPC performed at weeks 0 and 8.
Additionally each cat had a glomerular filtration rate
(GFR) estimated by iohexol clearance performed at
weeks 0 and 8. Iohexol clearance has been described as
a clinically applicable alternative to estimate GFR and
has previously been assessed in cats with reduced renal
function [28-30]. For this method, 300 mg/kg iohexol
(Omnipaque, GE Health Incorporated, Princeton, NJ,
USA) was administered intravenously, and blood sam-
ples were collected at 2, 3, and 4 h after administration.
Analysis is commercially available at the Michigan State
University Diagnostic Center for Population and Animal
Health. Assessment of GFR variability was performed by
enrolling three CKD cats that did not receive MSC ther-
apy but underwent estimation of GFR by iohexol clear-
ance at 0 and 8 weeks.
Pilot study 3
Each treated cat underwent physical examination,
weighing, and routine blood work consisting of CBC,
serum biochemistry, and urinalysis at weeks 0, 2, 4, 6
and 8. Each cat had a UPC performed at weeks 0 and 8.
Additionally, each cat had a GFR by nuclear scintigraphy
performed at weeks 0 and 8.
For the scintigraphy procedure, cats were sedated with a
standard sedation protocol (ketamine 10 mg/cat and
butorphanol 0.1 mg/kg intravenously once) at a standard
time before the procedure. A single nuclear technician
performed all of the procedures for each particular cat.
For each procedure 1.0 mCi of Tc99m-labeled diethylene
triamine penta-acetic acid (DTPA) (Cardinal Health,
Dublin, OH, USA) was injected intravenously via a cath-
eter placed in a standard location in each cat. Images were
obtained using GE Millennium SPECT system applicable
for small animal planar, whole body and single-photon
emission computed tomography (SPECT) imaging (GE
Healthcare, Waukesha, WI, USA). Three independent ra-
diologists evaluated the GFR data, and a mean GFR value
for each kidney as well as a global value was determined.
Urinary cytokine analysis
Urine cytokine concentrations were determined using
commercial ELISA kits, as we have described recently [31].
Briefly, urine concentrations of interleukin (IL)-6, IL-8,
and IL-10 were measured using feline specific ELISA kits
(R&D Systems), while monocyte chemoattractant protein
1 (MCP-1) and vascular endothelial growth factor (VEGF)
were measured using commercial canine MCP-1 and
VEGF kits respectively (R&D Systems). Urine transforming
growth factor β1 (TGF-β1) concentrations were measured
using an ELISA kit from Invitrogen (Camarillo, CA, USA).
Urine samples were collected by cystocentesis, and an
aliquot of urine was immediately frozen at −20°C andthen stored at −80°C for cytokine measurements. Sam-
ples were thawed immediately prior to analysis and kept
on ice during sample preparation. All samples were
centrifuged at 2000 rpm (350 g) for 5 minutes at 4°C,
and the supernatant was collected for analysis. With one
exception, ELISA kits were run according to manufac-
turer instructions for serum samples. As one exception,
urine samples were diluted 5-fold rather than 40-fold for
detection of TGF-β1.
Urine and serum creatinine concentrations were mea-
sured with a Roche Cobas Integra Chemistry Analyzer
(Roche Diagnostics Limited, West Sussex, UK) at the
Colorado State University Diagnostic Laboratory. All
reported cytokine concentrations were normalized for
differences in urine concentration as a urine cytokine-to
-urine creatinine ratio. In order to maximize cytokine
yield in the urine samples, additional sample processing
steps were performed as previously described prior to
running the IL-8, MCP-1, and VEGF ELISA kits [31].
Statistical analysis
Changes in GFR, serum creatinine, blood urea nitrogen
(BUN), electrolytes, urine protein-to-creatinine (UPC)
ratio, urine specific gravity, and packed cell volume
(PCV) data over time in the aMSC-injected cats were
compared statistically by means of repeated measures
analysis of variance (ANOVA) followed by Bonferroni’s
correction. Values were considered statistically different
for P <0.05. Statistical analyses were performed using
Prism5 software (GraphPad, La Jolla, CA, USA).
Results
Description of study cats
A total of 165 cats with CKD were screened for entry into
this series of pilot studies. In all, 52 cats were excluded for
geographical reasons (extensive travel required), 40 cats
were excluded due to concurrent illness, 18 cats were ex-
cluded due to end-stage disease, 13 cats were excluded as
the owners thought the study too complex, 11 cats were
excluded due to unstable disease, 8 cats were excluded for
anatomic abnormalities, and 2 cats were excluded due to
fractious attitude in hospital. Descriptive data for the 21
cats with CKD that were enrolled in the aMSC pilot stud-
ies are presented in Table 1. Two cats that were enrolled
in pilot study 3 were unable to finish the trial due to devel-
opment of unrelated illnesses. A summary of cat weights
throughout the study and aMSC dose by weight are
presented in Table 2. No statistically significant difference
in weight was seen in any pilot study as determined by a
Wilcoxon sign rank test.
Characterization of MSCs
During in vitro culture feline aMSCs were observed to
develop into a relatively homogeneous population of
Table 1 Summary of demographics of cats participating in the intravenous allogeneic cryopreserved studies
Cat no. Group Description IRIS CKD stage and creatinine (mg/dl) Treatment
1 Pilot study 1 10 yr MC DSH IRIS CKD II; creatinine: 2.5 2 × 106 MSCs intravenously × 3 treatments
2 Pilot study 1 15 yr FS DSH IRIS CKD III; creatinine: 3.5 2 × 106 MSCs intravenously × 3 treatments
3 Pilot study 1 7 yr MC Siamese IRIS CKD III; creatinine: 4.3 2 × 106 MSCs intravenously × 3 treatments
4 Pilot study 1 12 yr MC DLH IRIS CKD II; creatinine: 2.4 2 × 106 MSCs intravenously × 3 treatments
5 Pilot study 1 15 yr MC DSH IRIS CKD II; creatinine: 2.3 2 × 106 MSCs intravenously × 3 treatments
6 Pilot study 1 15 yr FS Siamese IRIS CKD III; creatinine: 3.5 2 × 106 MSCs intravenously × 3 treatments
7 Pilot study 2 11 yr MC DSH IRIS CKD II; creatinine: 1.9 4 × 106 MSCs intravenously × 3 treatments
8 Pilot study 2 11 yr FS DSH IRIS CKD II; creatinine: 2.6 4 × 106 MSCs intravenously × 3 treatments
9 Pilot study 2 18 yr FS DSH IRIS CKD II; creatinine: 2.8 4 × 106 MSCs intravenously × 3 treatments
10 Pilot study 2 15 yr MC DSH IRIS CKD II; creatinine: 2.2 4 × 106 MSCs intravenously × 3 treatments
11 Pilot study 2 7 yr MC DSH IRIS CKD III; creatinine: 3.7 4 × 106 MSCs intravenously × 3 treatments
12 Pilot study 2 15 yr MC DSH IRIS CKD II; creatinine: 2.3 Iohexol GFR repeatability only
13 Pilot study 2 16 yr MC DSH IRIS CKD II; creatinine: 2.1 Iohexol GFR repeatability only
14 Pilot study 2 16 yr MC DSH IRIS CKD II; creatinine: 1.8 Iohexol GFR repeatability only
15 Pilot study 3 9 yr MC DSH IRIS CKD II; creatinine: 2.6 Enrolled but decompensated before treatment initiated
16 Pilot study 3 15 yr MC Siamese IRIS CKD II; creatinine: 2.4 4 × 106 MSCs intravenously × 2 treatments before
recurrence of previous diabetes
17 Pilot study 3 13 yr MC Siamese IRIS CKD II; creatinine: 2.7 4 × 106 MSCs intravenously × 3 treatments
18 Pilot study 3 8 yr MC DSH IRIS CKD II; creatinine: 1.7 4 × 106 MSCs intravenously × 3 treatments
19 Pilot study 3 13 yr MC DSH IRIS CKD II; creatinine: 2.0 4 × 106 MSCs intravenously × 3 treatments
20 Pilot study 3 15 yr MC DLH IRIS CKD II; creatinine: 2.3 4 × 106 MSCs intravenously × 3 treatments
21 Pilot study 3 15 yr FS DSH IRIS CKD III; creatinine: 3.1 4 × 106 MSCs intravenously × 3 treatments
Six cats were enrolled in pilot study 1 and received 2 × 106 cryopreserved adipose-derived mesenchymal stem cells (aMSCs) per infusion. In pilot study 2 eight cats
were enrolled; five received 4 × 106 cryopreserved aMSCs per infusion, and three cats received only iohexol clearance studies. In pilot study 3, seven cats were enrolled;
five cats received 4 × 106 cryopreserved aMSCs cultured from cryopreserved adipose per infusion; two cats developed unrelated medical conditions and were removed
from the trial. CKD, chronic kidney disease; GFR, glomerular filtration rate. MC = male castrated, FS = female spayed, DSH = domestic shorthair, DLH = domestic long
hair, IRIS = International Renal Interest Society.
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Adipose-derived MSCs expressed high levels of CD44
and CD90 and were negative for expression of CD4 and
MHC class II (Figure 1). Both cryopreserved aMSCs and
aMSCs cultured from cryopreserved fat were capable of
trilineage differentiation (Figure 2).
Short-term responses to MSC injection
Cats in pilot study 1 treated with three separate intraven-
ous infusions of 2 × 106 cryopreserved aMSCs and cats in
pilot study 3 treated with three separate intravenous infu-
sions of 4 × 106 aMSCs cultured from cryopreserved fat
tolerated their injections without apparent adverse effects.
During the infusions and immediately after, the cats
appeared clinically normal and unperturbed. However,
cats in pilot study 2, each having received an intravenous
infusion of 4 × 106 cryopreserved aMSCs, experienced a
number of treatment-related adverse effects. The adverse
effects included vomiting (two cats) and increased respira-
tory rate (four cats). In two cats, vomiting and nausea oc-
curred within 2 minutes of initiating the first aMSC
infusion and were not associated with respiratory distress.Administration of diphenhydramine (1 mg/kg subcutane-
ously) and maropitant (1 mg/kg subcutaneously) resulted
in cessation of clinical signs of vomiting and nausea. Af-
fected cats were premedicated with diphenhydramine and
maropitant for subsequent treatments, and additional ad-
verse gastrointestinal reactions were not noted. One cat
that experienced vomiting at the time of the first injection
subsequently developed increased respiratory rate at the
time of the third aMSC injection.
Increased respiratory rate and effort following aMSC
infusion was not pronounced in three of the four pilot
study 2 cats that experienced respiratory signs but were
quite pronounced in one cat. Average baseline respira-
tory rate was 44 breaths/minute (range 36 to 60) and
average increased respiratory rate was 80 breaths/minute
(range 60 to 112 breaths/minute). Increased respiratory
rate and effort was generally noted after approximately
two-thirds of the aMSCs had been administered (that is,
after 30 minutes of infusion) in the three cats with mild
respiratory signs. One cat, however, had mildly increased
respiratory rate on the first infusion, a normal second in-
fusion, and developed marked overt respiratory distress
Table 2 Weight and mesenchymal stem cell (MSC) dose for cats participating in the intravenous allogeneic
cryopreserved MSC studies
Study Stage Weight in kg, median (range) MSC dose in cells/kg, median (range)
Pilot study 1, n = 6 Before 4.8 (2.7 to 5.1) 4.1 × 105 (3.9 × 105 to 7.4 × 105)
After 4.8 (2.5 to 5.2)
Pilot study 2, n = 5 Before 4.8 (4.4 to 6.2) 8.3 × 105 (6.1 × 105 to 9.1 × 105)
After 4.8 (4.2 to 7.1)
Pilot study 3, n = 5 Before 4.8 (3.7 to 7.1) 8.4 × 105 (5.6 × 105 to 1.1 × 106)
After 4.8 (3.5 to 7.1)
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the aMSCs had been administered. The respiratory dis-
tress was characterized by a sudden onset of increased
respiratory rate that quickly led to nasal flare, open
mouth breathing, and an orthopnic stance with head ex-
tended and elbows out. The injection was stopped, the
cat was moved to a critical care ward and placed in
an oxygen chamber, and diphenhydramine (1 mg/kgFigure 1 Expression of cell surface markers by cryopreserved feline a
expanded from cryopreserved adipose were passaged three times in cultur
of cell surface marker expression by flow cytometry, as described in Metho
(B) but did not express major histocompatibility complex (MHC) class II (C)
MSCs are represented in blue. Similar results were obtained with aMSCs frosubcutaneously) was administered. After 20 minutes no
improvement was noted, and the cat became notably
nauseated (foaming at the mouth and subsequently
vomiting). Maropitant (1 mg/kg subcutaneously) and
dexamethasone (0.05 mg/kg intravenously) were admin-
istered. Clinical signs began to abate within 20 minutes
of administration of dexamethasone. Open mouth
breathing and orthopnea improved within 1 h. Increaseddipose-derived mesenchymal stem cells (aMSCs). Feline aMSCs
e, then collected by trypsinization and immunostained for assessment
ds. Feline aMSCs expressed high surface levels of CD90 (A) and CD44
or CD4 (D). Isotype controls are represented in red and unstained
m three donor cats (E).
Figure 2 Trilineage differentiation of feline adipose-derived mesenchymal stem cells (aMSCs) after cryopreservation as cells or
adipose. aMSCs taken directly from cryopreservation (A-C) and cultured from cryopreserved adipose (D-F) were capable of trilineage
differentiation. (A,D) aMSCs formed intracellular lipid vacuoles when incubated in adipocytic differentiation media for 21 days. (B,E) aMSCs stained
positive for calcium with alizarin red following differentiation into osteocytic phenotype after 21 days of incubation in differentiation media.
(C,F) Cryosection of pellets of cartilage matrix (stained with toluidine blue) formed by aMSCs when exposed to chondrocytic differentiation media
for 21 days.
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post injection the cat was clinically normal and was
discharged without further incident.
Effects of MSC administration on renal function clinical
parameters
Serum creatinine concentrations decreased significantly
(P = 0.01) in pilot study 1 cats over the study period
but were unchanged in cats in pilot studies 2 and 3
(Figure 3A-C), however it is our opinion that the degree
of observed decrease (<0.5 mg/dl) in serum creatinine
concentrations is of questionable clinical significance. It
should be noted that one cat from pilot study 1 was re-
moved from analysis of serum creatinine concentration
because the owners failed to administer fluids during the
week prior to assessment, in violation of the study
protocol. Values for BUN, serum phosphorus, serum po-
tassium, packed cell volume, and urine specific gravity
or UPC did not change significantly following adminis-
tration of aMSCs as compared to pretreatment values in
any of the three pilot studies (Table 3).
Effects of aMSC administration on estimated glomerular
filtration rate
The GFR was not measured in pilot study 1 cats. In pilot
study 2 cats, there was an overall trend towards im-
provement in estimated GFR by iohexol clearance values
(P = 0.056), with individual increases of (75%, 10%, 61%,
7%, 6%) compared to untreated CKD control cats (7%, -18%,
-22%) (Figure 3D). In pilot study 3 cats there was
no statistically significant difference in total or individual
kidney GFR values as determined by nuclear scintigraphyhowever variable individual increases were seen (63%, 7%,
-34%, 13%, 91%) (Figure 3E).
Effects of aMSC administration on urinary cytokine
concentrations
In cats in pilot study 1, urine MCP-1 and IL-8 concen-
tration data following MSC administration as measured
by ELISA are depicted in Figure 4A,B. Using repeated
measures ANOVA, a statistically significant decrease in
MCP-1 (P = 0.0001) as well as in IL-8 (P = 0.01) was
detected. However due to the variability in cytokine con-
centration changes (some cats decreased significantly
while others increased), these results may not have clin-
ical relevance.
In cats in pilot studies 2 and 3, urine concentrations
of IL-8, MCP-1, TGF-β1 and VEGF were assessed
(Figure 2C-I). In the case of all four cytokines measured,
repeated measures ANOVA failed to detect any signifi-
cant changes in cytokine concentrations when pretreat-
ment urine cytokine concentrations were compared to
samples taken throughout the treatment period. In pilot
study 3, MCP-1 levels were inconsistently detected in
study samples.
Discussion
The safety and potential efficacy of repeated intravenous
administration of allogeneic cryopreserved feline aMSCs
to cats with naturally occurring CKD was assessed in
this series of pilot studies. MSCs have previously been
shown to be effective in suppressing some aspects of
renal disease in rodent models of induced CKD. How-
ever, MSC therapy has not been evaluated in a naturally
Figure 3 Assessment of renal function in adipose-derived mesenchymal stem cell (aMSC)-treated cats. (A) Serum creatinine values for
cats in pilot study 1, who received three doses of 2 × 106 cryopreserved aMSCs intravenously 2 weeks apart. A statistically significant decrease in
creatinine is seen (P = 0.01), however the degree of decrease may not be clinically significant. (B) Serum creatinine values for cats in pilot study 2,
who received three doses of 4 × 106 cryopreserved aMSCs intravenously 2 weeks apart. No significant difference in creatinine was detected.
(C) Serum creatinine values for cats in pilot study 3, who received three doses of 4 × 106 aMSCs cultured from cryopreserved adipose intravenously 2
weeks apart. No significant difference in creatinine was detected. (D) Estimated glomerular filtration rate (GFR) by iohexol clearance results at 0 and 8
weeks for five cats in pilot study 2 that received 4 × 106 cryopreserved aMSCs intravenously every 2 weeks for three treatments. Control chronic kidney
disease cats had GFR performed at 0 and 8 weeks only. (E) GFR determined by nuclear scintigraphy results at 0 and 8 weeks for five cats in pilot study
3 that received 4 × 106 aMSCs cultured from cryopreserved adipose intravenously every 2 weeks for three treatments.
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model. We modified existing rodent MSC administration
protocols to create a clinically feasible trial in cats with
CKD with translational potential. The major findings
from our preliminary studies of aMSC therapy were
that lower doses of allogeneic cryopreserved aMSCs
were well tolerated following repeated intravenousTable 3 Summary of clinicopathological data from cats partic







Pilot study 1 Before 3.5 (2.3 to 4.3) 57 (33 to 69) 3.8 (2.6 to 4.5)
After 3.2 (1.9 to 3.9) 53 (36 to 58) 3.7 (3.3 to 4.5)
Pilot study 2 Before 2.6 (1.9 to 3.7) 42 (34 to 61) 4.0 (3.6 to 4.2)
After 2.3 (1.8 to 3.9) 37 (30 to 64) 4.7 (2.4 to 6.7)
Pilot study 3 Before 2.3 (1.7 to 3.1) 49 (34 to 53) 4.2 (3.6 to 4.9)
After 2.5 (1.9 to 2.8) 42 (36 to 53) 3.8 (3.7 to 3.9)
No significant changes in clinicopathological parameters were seen as a result of readministration and appeared to be associated with mod-
est improvement in renal function. The level of improve-
ment in renal function seen in the treated cats is,
however, of uncertain clinical significance. The six cats
in pilot study 1 that received the 2 × 106 cryopreserved
aMSC dose experienced a statistically significant de-










4.6 (3.8 to 5.5) 31 (29 to 36) 0.1 (0.1 to 0.2) 1.016 (1.013 to 1.022)
4.2 (3.9 to 4.7) 28 (26 to 36) 0.1 (0.1 to 0.2) 1.016 (1.013 to 1.025)
4.6 (3.7 to 5.1) 31 (27 to 35) 0.1 (0.1 to 0.2) 1.016 (1.015 to 1.030)
4.6 (3.7 to 5.0) 29 (27 to 34) 0.1 (0.1 to 0.3) 1.017 (1.013 to 1.036)
4.7 (3.9 to 5.0) 34 (25 to 37) 0.1 (0.1 to 0.4) 1.017 (1.013 to 1.037)
4.7 (4.1 to 5.0) 33 (28 to 34) 0.1 (0.1 to 0.4) 1.019 (1.013 to 1.029)
peated MSC administration in any pilot group.
Figure 4 Urinary cytokine levels in mesenchymal stem cell (MSC)-treated cats. Pilot study 1 (A,B): cats received 2 × 106 cryopreserved
aMSCs intravenously every other week for three injections. (A) Monocyte chemoattractant protein 1 (MCP-1):urine creatinine ratio throughout the
study. There was a statistically significant decrease in MCP-1 (P = 0.0001). (B) Interleukin 8 (IL-8):urine creatinine ratio throughout the study. There
was a statistically significant decrease in IL-8 (P = 0.01). Pilot study 2 (C-E): cats received 4 × 106 cryopreserved aMSCs intravenously every other
week for three injections. Cytokine:urine creatinine ratio data throughout the study for (C) MCP-1, (D) IL-8, (E) transforming growth factor (TGF)-β1
and (F) vascular endothelial growth factor (VEGF). There was no statistically significant change in urinary cytokines in pilot study 2. Pilot study 3
(G-I): cats received 4 × 106 aMSCs cultured from cryopreserved adipose intravenously every other week for three injections. Cytokine:urine
creatinine ratio data throughout the study for (G) IL-8, (H) TGF-β1 and (I) VEGF. There was no statistically significant change in urinary cytokines in
pilot study 3.
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degree of this decrease (<0.5 mg/dl) is very small and
may not translate to any change in clinical disease. In
contrast, higher intravenous doses of cryopreserved
aMSCs were associated with a high incidence of adverse
effects and variable evidence of improvement in renal
function as evidenced by GFR estimated by iohexol
clearance. Most of the five cats in pilot study 2 that re-
ceived 4 × 106 cryopreserved aMSCs per injection expe-
rienced side effects, including vomiting during infusion
and increased respiratory rate and effort including overt
dyspnea in one case. Significant changes in serum
creatinine, GFR, and urinary cytokine concentrations
were not observed in pilot study 2 cats. In pilot study
3, cats that received 4 × 106 aMSCs cultured from
cryopreserved adipose experienced no side effects, but lit-
tle evidence of clinically significant improvement in renal
function. Thus, we concluded that although intravenousadministration of higher doses of cryopreserved, allogeneic
aMSCs was unlikely to be an acceptable treatment option
due to the high rate of complications and the lack of clin-
ical or experimental responses; aMSCs expanded from
cryopreserved fat appear a safer option although strong in-
dication of efficacy is still lacking.
A recent study by Semedo et al. [4] in a rat model of
CKD provided compelling evidence of the potential efficacy
of repeated intravenous administration of bone marrow-
derived MSCs for suppression of intrarenal inflammation
and fibrosis, and this treatment protocol was the one
we adapted for clinical application in CKD cats. Although
aMSCs were used instead of bone marrow-derived
MSCs, in the field of adipose stem cell research, the two
sources are felt to be comparable in characterization and
therapeutic potential in inflammatory disease states
[23-27,32,33]. Why then were the results of our prelimin-
ary studies of aMSC therapy in cats with CKD so different
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(based on body weight) were utilized? Firstly, differences in
the CKD model should be taken into consideration. Most
rodent models involve acute insult to the kidney with sub-
sequent administration of MSCs within a few weeks: a rela-
tively short time post renal insult [4,34]. Thus, the induced
disease models, with their relatively short time frame, may
not be representative of the changes occurring in a truly
chronic, naturally occurring disease process [11]. Cats have
an extended lifespan and often have CKD for months to
years prior to clinical diagnosis and study enrollment,
which is more similar to the disease time frame seen in
humans. The possibility that this potential therapy may not
be as effective in patients with more long-standing disease
should be considered.
Secondly, in our study, we utilized allogeneic aMSCs,
whereas autologous MSCs were used in the Semedo et
al. study [4]. The relative efficacy of autologous vs. allo-
geneic cells is an area of controversy. Although allogen-
eic MSCs are immune privileged and are not expected
to incite an immune response, according to some au-
thors they may not be as effective as autologous cells
[35]. It is argued that autologous MSCs may survive lon-
ger in the body in comparison to allogeneic cells, which
could reduce efficacy of the latter. Decreased efficacy of
allogeneic MSCs in comparison to autologous MSCs has
been observed in one acute renal failure rodent study
[35]. However, allogeneic MSCs have been widely used
in experimental stem cell transfer investigations, including
clinical trials in humans, with positive results [35,36].
A third major difference was the use of freshly-thawed,
cryopreserved aMSCs in pilot studies 1 and 2. This de-
cision was made based on the logistical ease afforded by
use of cryopreserved rather than freshly-cultured MSCs.
Successful cryopreservation of cells has been previously
described [37]. However, it is unknown if cryopreserva-
tion affects the functional properties of aMSCs necessary
for successful use in this model. Previous studies assessing
the effects of cryopreservation on MSCs did not examine
effects on potential immunogenicity and further work is
needed to fully assess this subject [37,38].
Based on the results of the three pilot studies, it ap-
pears that use of higher doses of cryopreserved aMSCs
was the source of the treatment-related adverse effects
in pilot study 2 as similar doses of aMSCs cultured from
cryopreserved adipose tissue did not result in any ad-
verse effects. Although the specific reasons for the in-
creased incidence of side effects is not known, it is likely
related to the increase in dose of cryopreserved cells.
The most likely explanation for this reaction is an in-
stant blood mediated inflammatory reaction (IBMIR)
which results in clumping of the cells as they contact
the blood and potential subsequent micro pulmonary
thromboembolism [39]. The IBMIR phenomenon hasbeen described previously in cryopreserved cells and in-
creases in severity with dose and passage number [39]. It
can result in lysis of the administered MSCs and subse-
quent poor efficacy. Although all cells given in pilot
study 2 were of the same passage (P3) as those used in
the other two pilot studies, the reaction was only seen in
the pilot study group where cells were taken directly
from cryopreservation and used at the higher dose. In
pilot study 3 no complications during or after adminis-
tration of aMSCs cultured from cryopreserved fat were
appreciated. Thus, we have concluded that the adminis-
tration of a higher dose of aMSCs taken directly from
cryopreservation, despite careful washing, was the
source of the toxic reactions observed, and this form of
administration is not recommended.
Although several cats in the pilot study 1 group expe-
rienced a statistically significant improvement in serum
creatinine concentrations during the study, the degree of
increase is unlikely to be clinically significant. Creatinine
is not the most sensitive measurement of renal function
even though it is the routinely measured clinical marker
of renal function. Several factors that are not directly re-
lated to renal function can influence serum creatinine
values, including muscle mass and hydration status
[28,40]. Decreases in weight and/or muscle mass can
potentially decrease serum creatinine, while a worsening
in hydration status can increase serum creatinine. In
addition, changes to renal function may occur without
any concomitant alteration in serum creatinine, although
this is thought to be less true once an animal reaches
the stage of moderate renal dysfunction [28]. Although
there were no significant changes in body weight noted
in these pilot studies, individual changes in body weight
in the study cats could potentially have confounded
serum creatinine measurements, while changes in blad-
der fullness at the time of weighing could potentially
have compromised weight values. Therefore, in cats in
pilot studies 2 and 3 we also measured estimated GFR,
as a more objective way to monitor changes in renal
function. Quantitating GFR allowed us to assess poten-
tial overall kidney function changes induced by the para-
crine and/or autocrine effects of MSC administration.
GFR results were variable in cats in pilot studies 2 and
3; two of five animals in pilot study 1 and two of five
cats in pilot study 3 did experience a marked increase
from pretreatment baseline; however the change in GFR
was not significant overall for the group. Overall, defini-
tive evidence of significant efficacy of intravenous ad-
ministration of allogeneic aMSCs for treatment of CKD
in cats is lacking at this time. Closer evaluation of the
mechanism of MSC action in CKD, effect of disease stage,
necessary cell dosage (for example, a cell/kg dose rather
than a per cat dose as used in these pilot studies), timing
of injections, and other variables remain to be determined.
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The safety and potential efficacy of repeated intravenous
administration of allogeneic cryopreserved feline aMSCs
to cats with naturally occurring CKD was assessed in
this preliminary study. The major findings from our pilot
studies of aMSC therapy in cats with CKD were that
lower doses of allogeneic cryopreserved aMSCs were
well tolerated following repeated intravenous administra-
tion and appeared to be associated with modest decrease
in serum creatinine. In contrast, higher intravenous doses
of cryopreserved aMSCs were associated with a high inci-
dence of adverse effects and only modest evidence of func-
tional improvement in renal function. Thus, we concluded
that intravenous administration of higher doses of
cryopreserved, allogeneic aMSCs was unlikely to be an ac-
ceptable treatment option due to the high rate of compli-
cations and the lack of clinical or experimental responses.
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